This excerpt taken from the TPTX 10-K filed Mar 29, 2007.
Bisnorcymserine for Alzheimers Disease
Bisnorcymserine, or BNC, is a potential treatment to improve the symptoms of patients with severe Alzheimers disease. A butyrylcholinesterase inhibitor, BNC selectively inhibits butyrylcholinesterase, an enzyme similar to acetylcholinesterase. Normally these two enzymes coexist throughout the body, with acetylcholinesterase predominating in degrading acetylcholine. In the brain of Alzheimers disease patients, as acetylcholinesterase levels gradually fall, there appears to be a concomitant increase in butyrylcholinesterase levels in specific nerve pathways within areas of the brain associated with Alzheimers disease. Like acetylcholinesterase, butyrylcholinesterase degrades acetylcholine, decreasing the availability of this key neurotransmitter. BNC, by blocking the action of butyrylcholinesterase, should increase the availability of acetylcholine, potentially improving memory and cognition. We plan to complete the current on-going preclinical studies and seek development partners for BNC.